Diagnostic value of Novel Thrombus Markers in COPD with Deep Venous Thrombosis.

Background: This study assesses the diagnostic value of new thrombosis markers, including thrombin antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (t-PAIC), for the incidence prediction of deep venous thrombosis (DVT) of lower limb in chronic obstructive pulmonary disease (COPD) patients.

Methods: 98 patients with COPD admitted to Shenzhen Guangming district people's hospital from March 2020 to May 2022 were selected and divided into a non-DVT group (n=62) and a DVT (n=36) group. A control group consisting of 50 healthy subjects was recruited. The blood sugar and lipid metabolic indicators of patients in each group were analyzed and compared. ROC curve analysis was performed to assess the diagnostic efficacy of new thrombosis markers.

Results: There were no significant differences in the levels of fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) among the three groups. The DVT group exhibited higher levels of fibrin degradation product (FDP) and D-dimer (D-D) than the non-DVT group. The plasma levels of TAT, PIC, TM, and t-PAIC in the DVT group significantly elevated compared to the other two groups. Combined diagnosis of TAT and TM displayed superior diagnostic efficacy with maximum AUC values (0.833) and a sensitivity of 87.5%.

Conclusions: The detection of serum levels of TAT, PIC, TM, and t-PAIC have diagnostic value in COPD patients with DVT.